The Development Engine: India’s CRO/CDMOs and the Manufacturing Edge

India’s biotech clusters are no longer defined solely by vaccine and generics production. In Genome Valley, the rapid rise of CROs and CDMOs has created a dense, end-to-end backbone that supports everything from early discovery to commercial manufacturing. This shift raises a sharper question: can India’s contract research and manufacturing sector turn speed, modular design, and integrated platforms into a lasting edge over global rivals? Signals from Hyderabad, Pune, and Gujarat suggest the answer lies in agility—plug-and-play facilities, hybrid service models, and AI-enabled process integration—that could reposition India from “pharmacy of the world” to a preferred global biotech partner by 2030.

From Discovery to Delivery

As India’s life sciences clusters mature, Genome Valley is increasingly distinguished not just by vaccine and biopharma manufacturing, but by its dense CRO/CDMO backbone—a supporting infrastructure that enables agile, end-to-end innovation and production. Syngene, with more than 600 global clients, supports discovery-to-commercial research services across small molecules and biologics; Sai Life Sciences, which partners with over 200 innovator companies, specializes in process chemistry and development at scale; Aurigene, with over 15 assets licensed to multinational pharma, focuses on oncology and autoimmune drug discovery; and Cohance, backed by Advent International, integrates multiple CDMO platforms to deliver end-to-end biologics development and manufacturing.

Its density provides speed: plug-and-play facilities can be operational in three to five months, enabling scale-up from discovery to global delivery and positioning Genome Valley as one of the world’s most concentrated life sciences production hubs, carving out India’s role in the global biotech supply chain.

1. Hyper-Modular, Plug-And-Play Facilities

The claim that new facilities can be operational in 3–5 months is no longer hyperbole—it is becoming the benchmark. To compete, new entrants and expansions will invest in pre-validated modular cleanrooms, interoperable process skids, and “digital twin” validations so that unit operations (e.g. cell culture, chromatography, filling) can be swapped in or out quickly. Indian players such as Bharat Biotech and Biological E in Hyderabad have already expanded capacity using modular vaccine manufacturing units, while Gland Pharma has adopted flexible biologics suites designed for faster turnaround. Standardization of utilities (HVAC, steam/DI water, waste systems) and compliance with global regulatory modules (e.g. FDA, EMA, ICH) from day one will be key.

How this differs from the rest of the world: In the U.S. or Europe, modular facilities are also being deployed, but the process often involves higher regulatory scrutiny, longer permitting cycles, and higher capital costs. In India, the combination of lower construction costs, government incentives for biotech infrastructure, and cluster effects in hubs like Genome Valley and Pune makes these timelines genuinely compressible to just a few months. While Western sites may prioritize ultra-customized builds for blockbuster biologics, India’s edge lies in standardized, pre-validated modules that can switch between vaccine, biosimilar, or small-molecule production. This agility allows Indian CRO/CDMOs to capture fast-moving global contracts, particularly for emerging markets where speed and cost are decisive.

2. Integrated Small Molecule + Biologics Capabilities Under One Roof

Historically, many Indian CDMOs specialized in either small-molecule chemistry or biologics. The next wave emphasizes convergence: hybrid CRO/CDMOs that can take a candidate from medicinal chemistry through cell line development, scale-up, viral vectors, and fill/finish. For example, Dr. Reddy’s in Hyderabad has expanded from its stronghold in generics and chemistry services into biologics manufacturing, while Zydus Lifesciences is building capacity that spans both therapeutic antibodies and small-molecule APIs. Gland Pharma, traditionally focused on injectables, is moving into biologics development and manufacturing, further blurring these boundaries.

Why this matters: This shift reduces handoffs, shortens timelines, and gives clients one “trusted partner” rather than multiple vendors. For biotech innovators, that translates into faster progression from discovery to IND filing and fewer regulatory delays caused by fragmented supply chains.

How India compares globally:

• China (WuXi AppTec, WuXi Biologics): Chinese CDMOs built scale early, offering end-to-end services across small molecules and biologics, but they remain highly export-driven and vulnerable to geopolitical headwinds.
• Europe (Lonza, Switzerland): European CDMOs are strong in biologics, cell, and gene therapy, but typically command premium pricing, making them less accessible for smaller biotechs.
• United States (Catalent, Thermo Fisher, Samsung Biologics’ U.S. presence): U.S. CDMOs dominate the high-value segment, focusing on advanced biologics, cell and gene therapies, and precision manufacturing. They are deeply integrated into the domestic biotech pipeline, often serving as the first choice for venture-backed startups aiming at the U.S. FDA market. However, high labor and operating costs, coupled with capacity bottlenecks, make them less competitive for large-volume or cost-sensitive projects.
• India’s niche: By combining cost efficiency in small-molecule chemistry with a growing biologics infrastructure, India can deliver integrated services at a fraction of Western costs, without the political risks tied to China. This makes Indian CDMOs increasingly attractive for mid-sized biotech firms in the U.S., Europe, and Asia seeking both affordability and speed.

In effect, India’s ability to converge small-molecule and biologics under one roof is more than a technical upgrade—it is a strategic positioning move, allowing its CRO/CDMO sector to compete directly with global incumbents while differentiating itself on flexibility, cost, and geopolitical neutrality.

3. Platform Technologies & Plug-In Modules

Investing in platforms—e.g. platform antibodies (Fc scaffolds), mAb conjugation, biologic expression systems (CHO, yeast, insect cells), and viral-vector platforms (AAV, lentivirus)—lets providers amortize costs across multiple projects. Biological E in Hyderabad, for instance, has developed standardized vaccine platforms that can be adapted to different antigens, while Intas Pharmaceuticals in Ahmedabad has invested heavily in monoclonal antibody platforms to support biosimilar and novel biologic pipelines. Similarly, Zydus Lifesciences has built plug-and-play modules for both therapeutic proteins and antibody-drug conjugates.

What this means: Instead of reinventing processes from scratch for each client project, CDMOs can reuse proven platforms. This drastically reduces time and technical risk—whether for scaling an antibody therapy, developing a new viral vector, or bringing a vaccine candidate into clinical production.

Why it’s relevant: For smaller biotech firms and academic spinouts, the ability to “plug in” a gene or small molecule into an already validated system lowers barriers to entry. It means they can access industrial-scale processes without raising billions in venture capital. For India, these modular platforms enhance global competitiveness: they allow domestic CDMOs to serve multiple international clients simultaneously, move faster in outbreak response (as seen in COVID-19 vaccine pivots), and offer cost-effective access to advanced modalities that are often prohibitively expensive in the U.S. or Europe.

4. Advanced Analytics, AI & Digital Integration

More CRO/CDMO firms are embedding real-time analytics, process monitoring, predictive modeling, and AI into their operations to accelerate process optimization. A digital pipeline from lab → pilot → GMP scale is becoming essential, with digital twins and simulations helping reduce experimental runs and avoid scale-up surprises. Basically, a digital pipeline from lab to pilot to GMP scale is becoming increasingly important, as each step magnifies complexity and cost. What works in a flask rarely behaves the same way in a 1,000-liter bioreactor, and unexpected deviations can trigger failed batches or regulatory setbacks. Digital twins and process simulations allow CROs and CDMOs to model these conditions before committing to physical runs. By running virtual experiments first, firms can identify bottlenecks, fine-tune parameters, and anticipate where scale-up surprises might occur. The result is fewer wasted runs, more predictable quality, and a smoother path from discovery to commercial production.

Aragen Life Sciences in Hyderabad has integrated predictive analytics into its chemistry and biologics workflows, while Laurus Labs has been investing in AI-driven bioinformatics and process modeling. These examples indicate how the related upgrades allow clients to see risks and adjust earlier in development.

Why this matters: Instead of relying on trial-and-error, companies can simulate production runs, forecast yields, and optimize parameters before going into manufacturing. For multinational clients, this means faster timelines and fewer costly failures. For India, it provides a technological edge that enhances credibility in regulated markets.

5. Quality & Regulatory Readiness As Value Differentiators

In today’s market, clients expect CDMOs to be more than manufacturing vendors. They want partners capable of preparing submission-ready data packages for global regulators like the FDA and EMA. That requires early adoption of ICH Q12 standards, Quality by Design (QbD) principles, and modular regulatory submissions.

For example, Biocon Biologics has demonstrated the ability to navigate U.S. and European approvals with its biosimilars, showing that Indian firms can meet stringent global requirements. Aurobindo Pharma has built compliance systems for biologics and injectables that allow it to compete in advanced regulated markets.

Why this matters: Strong regulatory infrastructure transforms India’s value proposition. Instead of being seen as only a low-cost supplier, Indian CDMOs position themselves as trusted global partners, capable of handling complex compliance needs alongside production. This upgrade is critical if India wants to win higher-value contracts from Europe and the U.S.

6. Flexible Business Models & Risk Sharing

The old model of charging fixed fees for services is giving way to new approaches where CDMOs share risk with their clients. Some companies are experimenting with milestone-based payments, revenue sharing, or even equity stakes in the biotech firms they support. 

In India, this shift is starting to take shape as well, with leading players testing out creative partnership models to attract global biotech clients. Jubilant Pharmova has tried hybrid contracts where research services are paired with financial investment, aligning its incentives with the client’s success. Intas has offered milestone-linked payment terms to lower upfront costs for biosimilar partners.

Why it’s relevant: Smaller biotech firms often cannot afford heavy upfront payments but still need high-quality development and manufacturing partners. By offering flexible contracts, Indian CDMOs make themselves more attractive to early-stage companies globally, ensuring a steady pipeline of projects and partnerships.

7. Geographic Clustering, Supply Chain Resilience, And Logistics Integration

India’s CRO/CDMO sector benefits from geographic concentration in biotech hubs where research, manufacturing, and logistics sit side by side. Genome Valley in Hyderabad, for example, houses Bharat Biotech, Indian Immunologicals, and a dense network of CDMOs and suppliers. Gujarat’s pharma corridor and Bengaluru’s biotech hub follow similar patterns, combining research, production, and supply-chain infrastructure in close proximity.

In Genome Valley, firms can access everything from preclinical CROs to fill-finish CDMOs and cold-chain providers within a few kilometers. Gujarat has a similar advantage for APIs and formulations, with manufacturing plants integrated into export infrastructure.

Why this matters: These clusters reduce handoffs and create “one-stop shop” ecosystems. For clients, that means fewer delays and lower risks when moving from lab to market. For India, clustering amplifies its appeal as a global outsourcing hub by offering both speed and scale, something harder to replicate in fragmented ecosystems elsewhere.

How it differs globally: In the United States, biotech activity is concentrated in hubs like Boston–Cambridge or the Bay Area, but the supply chain is often spread across multiple states, leading to longer timelines and higher coordination costs. Europe has strong hubs in Switzerland, Germany, and the U.K., but they tend to specialize—Basel in biologics, Oxford in advanced therapies—rather than integrating every stage within a single cluster. China has rapidly built end-to-end hubs in cities like Shanghai and Suzhou, but many facilities remain heavily export-focused and face regulatory or geopolitical uncertainties. India’s advantage lies in the tight integration of research, manufacturing, and logistics within a single geography, paired with cost efficiency and global regulatory alignment, giving it a unique edge in speed and scalability.

Not Just the World’s Pharmacy Anymore

Together, these elements show how India’s base infrastructure has diversified: USFDA-compliant plants provide global credibility, Genome Valley offers a cluster model that integrates R&D with manufacturing, and the Serum Institute illustrates how scale can translate into both access and influence. The question ahead is how these assets can be aligned toward drug discovery, AI-enabled R&D, and global partnerships—shifting India’s position from “pharmacy of the world” to a broader biotech innovator by 2030.

Author

Bernice Lottering